SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genaissance Pharmaceuticals (GNSC)
An SI Board Since September 2000
Posts SubjectMarks Bans Symbol
183 6 0 GNSC
Emcee:  Jim Oravetz Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
8Genaissance Pharm:Deutsche Banc Alex. Brown raises price target to $50 from $30,Jim Oravetz-11/3/2000
7Call replay: In conjunction with the release of its financial results for Jim Oravetz-11/3/2000
6"These financial results are in line with our expectations and reflect the Jim Oravetz-11/3/2000
5The Smart Way to Play DNA : ....SNPs SNPs (single nucleotide polymorphisms), Jim Oravetz-10/6/2000
4Largely powered by Yale-related money and brainpower, an explosion of investmentJim Oravetz-9/13/2000
3Welcome aboard nigel. Looks like some interesting work has already been done atJim Oravetz-9/12/2000
2Sept. 12 /PRNewswire/ -- Researchers at Genaissance Pharmaceuticals, Inc. (Nasdanigel bates-9/12/2000
1IPO From Population-Genomics Firm Genaissance Makes Strong Debut Jim Oravetz-9/8/2000
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News